We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

British Columbia’s HPV Vaccination Program Reduces Cervical Pre-cancer Rates by > 50%

Rectangle Image
News

British Columbia’s HPV Vaccination Program Reduces Cervical Pre-cancer Rates by > 50%

Read time:
 

The evaluation of the HPV vaccination program in B.C. was conducted jointly by researchers at the University of British Columbia (UBC), BC Cancer, the BC Centre for Disease Control, and BC Women’s Hospital and Health Centre and highlights the success of the program in reducing pre-cancers. Pre-cancer refers to abnormal cell growth in the cervix most often discovered during routine Pap tests. If not treated, pre-cancer can develop into cervical cancer.

The study was recently published in the Journal of Infectious Diseases.

The study found that B.C. women who had received the HPV vaccine as grade six girls had a 57 per cent reduction in the incidence of cervical pre-cancer cells.

This study contributes to the growing body of evidence highlighting the positive impact of the HPV vaccine and regular cervical screening on preventing cervical cancer.
Dr. Gina Ogilvie

HPV has been identified as the cause of almost all cervical cancers. In 2008, the Province of British Columbia implemented a voluntary publicly funded school-based HPV immunization program. Eleven years later, the first groups of women vaccinated through this program have reached adulthood and entered the Cervix Screening Program. By linking records from the provincial Cervix Screening Program with immunization registries, researchers were able to compare outcomes between the women who had received vaccinations to those who had not.

Women included in the study received the quadrivalent vaccine, which protects against two types of HPV responsible for approximately 70 per cent of all cervical cancers. The HPV vaccine that is now administered in the school-based program protects against seven types of the virus that cause about 90 per cent of cervical cancers. As today’s grade six girls receive a more comprehensive vaccine, rates of pre-cancer are expected to decline even further in coming years.

“We are excited by these initial findings,” says Dr. Gina Ogilvie, professor, School of Population and Public Health, UBC and senior research advisor, BC Women’s Hospital and Health Centre. “This study contributes to the growing body of evidence highlighting the positive impact of the HPV vaccine and regular cervical screening on preventing cervical cancer. And, with increased vaccine uptake we would expect to see a further decrease in cervical cancer rates.”

HPV is common in both men and women and can be easily spread through sexual contact. Most people will contract HPV at some point in their lives and it is important to get vaccinated before becoming sexually active. The vaccine is now available for free to both girls and boys in grade six and protects against cervical, anal and some rare penile cancers.

Although most HPV infections clear up on their own, some cause pre-cancerous lesions that can develop into cancer over time if they’re not treated. It can take more than ten years for pre-cancerous cells to develop into cervical cancer. Regular cervical cancer screening is important to identify abnormal or pre-cancerous cells, before they cause symptoms.

“The HPV immunization program in BC is in its 12th year in BC now, and it’s very gratifying to be able to show such positive outcomes through prevention of this infection and its complications in women,” said Dr. Monika Naus, professor at the School of Population and Public Health at UBC and medical director, Communicable Diseases & Immunization Service.

Reference: Racey, et al. (2019) Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program. Journal of Infectious Diseases. DOI: https://doi.org/10.1093/infdis/jiz422 

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement